Semanteon Capital Management LP Makes New $472,000 Investment in Evolus, Inc. (NASDAQ:EOLS)

Semanteon Capital Management LP purchased a new position in Evolus, Inc. (NASDAQ:EOLS) in the fourth quarter, Holdings Channel.com reports. The firm purchased 44,786 shares of the company’s stock, valued at approximately $472,000.

Other large investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in shares of Evolus by 13.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock worth $113,000 after purchasing an additional 1,484 shares during the period. Swiss National Bank raised its stake in Evolus by 1.8% during the third quarter. Swiss National Bank now owns 93,800 shares of the company’s stock valued at $857,000 after purchasing an additional 1,700 shares in the last quarter. Kestra Advisory Services LLC raised its stake in Evolus by 18.5% during the third quarter. Kestra Advisory Services LLC now owns 16,356 shares of the company’s stock valued at $149,000 after purchasing an additional 2,550 shares in the last quarter. Brandywine Global Investment Management LLC raised its stake in Evolus by 1.9% during the third quarter. Brandywine Global Investment Management LLC now owns 158,200 shares of the company’s stock valued at $1,446,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Barclays PLC raised its stake in Evolus by 24.5% during the third quarter. Barclays PLC now owns 19,794 shares of the company’s stock valued at $181,000 after purchasing an additional 3,889 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Price Performance

Shares of EOLS traded down $0.03 during midday trading on Friday, hitting $11.43. The stock had a trading volume of 248,985 shares, compared to its average volume of 610,462. Evolus, Inc. has a 1 year low of $7.07 and a 1 year high of $15.43. The firm has a market cap of $662.25 million, a PE ratio of -10.49 and a beta of 1.45. The stock’s 50 day moving average is $13.43 and its 200 day moving average is $11.24.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to analysts’ expectations of $61.14 million. As a group, equities research analysts expect that Evolus, Inc. will post -0.51 earnings per share for the current fiscal year.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 6,236 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $13.86, for a total value of $86,430.96. Following the transaction, the insider now directly owns 689,614 shares in the company, valued at $9,558,050.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Evolus news, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the transaction, the chief financial officer now directly owns 154,201 shares in the company, valued at approximately $2,146,477.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Moatazedi sold 6,236 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $13.86, for a total transaction of $86,430.96. Following the transaction, the insider now owns 689,614 shares in the company, valued at $9,558,050.04. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,969 shares of company stock worth $831,005. Insiders own 5.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on EOLS shares. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Friday, March 1st. Barclays raised shares of Evolus from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $10.00 to $16.00 in a research note on Monday, January 29th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, April 10th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.